Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion. Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells. Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits-including durable responses--to patients with different malignancies. However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1…”
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 2×
“…and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10,22,26 .”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 4×
“Our findings provide some of the first experimental support for the clinical observations that (1) checkpoint blockade therapy amplifies, in some cases, preexisting anti-tumour T-cell responses(8,9,21,22); (2) whereas anti-CTLA-4 treatment eliminates regulatory T cells, promotes T-cell priming, and renders the host mo…”
InfluentialImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“To increase the robustness and accuracy of our epitope predictions, we modified our method as follows: (1) mutation calls from cDNA Capture Sequencing14 were translated to corresponding protein sequences, pipelined through three MHC class I epitope-binding algorithms and a median binding affinity calculated for each p…”
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“…and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10,22,26 .”
Self-citationSkyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“Elevated LAG-3 and TIM-3 expression is known to mark antigen-experienced, dysfunctional (i.e., exhausted) CD8 + T cells 16,17 in chronic viral infection.”
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 4×
“Rejection was immunologic because (1) it was ablated by administration of monoclonal antibodies (mAbs) that either deplete CD4(1) or CD8(1) cells or neutralize interferon-c (IFN-c); (2) it did not occur in Rag2 mice lacking T, B and natural killer T (NKT) cells or Batf3 mice lacking CD8a(1)CD103(1) dendritic cells req…”
InfluentialSelf-citationBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 3×
“…8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is…”
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Self-citationSelected reaction monitoring for quantitative proteomics: a tutorial
Lange, V., Picotti, P., Domon, B., & Aebersold, R. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.61 · Cited by 1,407 · cited 1×
“Optimal SRM transition conditions (collision energy and fragment ion selection) were determined for individual peptides as previously described by using synthetic peptides 44 .”
Self-citationCancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288 · cited 4×
“Based on our previous success using genomics approaches to identify TSMA responsible for the spontaneous rejection of highly immunogenic, unedited MCA sarcomas 14 , we asked whether a similar approach could identify antigens responsible for α PD-1-mediated rejection of d42m1-T3 progressor tumours.”
InfluentialSelf-citationNeutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810 · cited 1×
“The ability to rapidly and accurately identify TSMA using genomics and bioinformatics approaches 18–20 and use them to generate MHC tetramers to identify tumour-specific T cells provides a significant advantage to the fields of tumour immunology and cancer immunotherapy.”
Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808 · cited 1×
“The Stabilized Matrix Method (SMM) algorithm 32 , the Artificial Neural Network (ANN) algorithm 33 , and the NetMHCpan algorithm 34 provided by the Immune Epitope Database and Analysis Resource (http:// www.immuneepitope.org) was used to predict epitope processing and binding affinities and the…”
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Self-citationNetMHCpan, a method for MHC class I binding prediction beyond humans
Hoof, I., Peters, B., Sidney, J., Pedersen, L. E., Sette, A., Lund, O., Buus, S., & Nielsen, M. (2009) · Immunogenetics · doi:10.1007/s00251-008-0341-z · Cited by 753 · cited 1×
“The Stabilized Matrix Method (SMM) algorithm 32 , the Artificial Neural Network (ANN) algorithm 33 , and the NetMHCpan algorithm 34 provided by the Immune Epitope Database and Analysis Resource (http:// www.immuneepitope.org) was used to predict epitope processing and binding affinities and the…”
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745 · cited 1×
“…and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10,22,26 .”
Self-citationOptions and considerations when selecting a quantitative proteomics strategy
Domon, B., & Aebersold, R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1661 · Cited by 605
Self-citationUsing i RT, a normalized retention time for more targeted measurement of peptides
Escher, C., Reiter, L., MacLean, B., Ossola, R., Herzog, F., Chilton, J., MacCoss, M. J., & Rinner, O. (2012) · PROTEOMICS · doi:10.1002/pmic.201100463 · Cited by 600 · cited 1×
“Retention times were extracted from the spectra and converted into a system-independent retention time (iRT) using spiked-in calibration peptides (Biognosys) 45 .”
Peters, B., & Sette, A. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-132 · Cited by 512 · cited 1×
“The Stabilized Matrix Method (SMM) algorithm 32 , the Artificial Neural Network (ANN) algorithm 33 , and the NetMHCpan algorithm 34 provided by the Immune Epitope Database and Analysis Resource (http:// www.immuneepitope.org) was used to predict epitope processing and binding affinities and the…”
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Nielsen, M., Lundegaard, C., Lund, O., & Keşmir, C. (2005) · Immunogenetics · doi:10.1007/s00251-005-0781-7 · Cited by 491
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419 · cited 1×
“…8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is…”
Self-citationDesign and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 347 · cited 1×
“The peptide-MHC class I complexes refolded with a UV-cleavable conditional ligand were prepared as described with modifications 37 .”
Self-citationPaul, S., Weiskopf, D., Angelo, M. A., Sidney, J., Peters, B., & Sette, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302101 · Cited by 298 · cited 1×
“1d) (epitope binding affinity distributions to different class I alleles are distict 15 ).”
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276 · cited 1×
“…support for the clinical observations that (a) checkpoint blockade therapy amplifies, in some cases, pre-existing anti-tumour T cell responses 8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23…”
Self-citationBystander elimination of antigen loss variants in established tumors
Spiotto, M. T., Rowley, D. A., & Schreiber, H. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260 · cited 1×
“For these types of tumours, it is likely that TSMA vaccines targeting multiple antigens will be possible thereby providing better coverage of the tumour cell population in part due to dealing more effectively with tumour heterogeneity 27,28 .”
HLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190 · cited 1×
“The ability to rapidly and accurately identify TSMA using genomics and bioinformatics approaches 18–20 and use them to generate MHC tetramers to identify tumour-specific T cells provides a significant advantage to the fields of tumour immunology and cancer immunotherapy.”
Antigen Bias in T Cell Cross-Priming
Wolkers, M. C., Brouwenstijn, N., Bakker, A. H., Toebes, M., & Schumacher, T. N. M. (2004) · Science · doi:10.1126/science.1096268 · Cited by 181 · cited 1×
“For these types of tumours, it is likely that TSMA vaccines targeting multiple antigens will be possible thereby providing better coverage of the tumour cell population in part due to dealing more effectively with tumour heterogeneity 27,28 .”
Self-citationTIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178
Self-citationAntigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175 · cited 1×
“Additionally, the combination of a TSMA vaccine and checkpoint blockade may facilitate the immune system’s ability to recognize less immunogenic TSMA as well as shared, tumour-associated antigens (TAA) via mechanisms that mimic epitope-Gubin spreading 29 .”
Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load
West, E. E., Youngblood, B., Tan, W. G., Jin, H.-T., Araki, K., Alexe, G., Konieczny, B. T., Calpe, S., Freeman, G. J., Terhorst, C., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.017 · Cited by 144
Self-citationEsquivel-Guadarrama, F. R., Yewdell, J. W., & Bennink, J. R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.163 · Cited by 137 · cited 1×
“The peptide-MHC class I binding assay with RMA-S cells 36 was performed by incubating RMA-S cells with serial dilutions of peptides for 24 h. Cells were stained with mAbs to H-2K b and H-2D b followed by secondary PE-conjugated goat anti-mouse Ig (BD Biosciences) and analysed by flow cytometry.”
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Andersen, R. S., Kvistborg, P., Frøsig, T. M., Pedersen, N. W., Lyngaa, R., Bakker, A., Shu, C. J., Straten, P. T., Schumacher, T. N., & Hadrup, S. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.037 · Cited by 132 · cited 1×
“…and purified by gel filtration FPLC. UV-induced ligand exchange and combinatorial encoding of MHC Class I multimers was performed as described 38 , except that the peptide-MHC multimers used for flow cytometry staining were prepared by the addition of titrated amounts of…”
Self-citationBiochemical Large-Scale Identification of MHC Class I Ligands
Kowalewski, D. J., & Stevanović, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-218-6_12 · Cited by 76
Thommen, D. S., Schuster, H., Keller, M., Kapoor, S., Weinzierl, A. O., Chennakesava, C. S., Wang, X., Rohrer, L., von Eckardstein, A., Stevanović, S., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101506 · Cited by 12 · cited 1×
“For the discovery mass spectrometry 41 , mass spectrometry analysis was performed on an LTQ OrbitrapXL hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a nanoelectron spray ion source coupled to a reverse-phase liquid chromatography UHPLC system (Ultimate 3000…”
Self-citation
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“Due to the non-overlapping mechanism of action of anti-CTLA4 and anti-PD1 antibodies (Das et al., 2015; Gubin et al., 2014), clinical testing of the combination of these two classes of checkpoint inhibitors showed improved clinical response (up to 60”
InfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Metadata
- Authors
- Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S. K., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., Schumacher, T. N., Aebersold, R., Rammensee, H.-G., Melief, C. J. M., Mardis, E. R., Gillanders, W. E., Artyomov, M. N., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- German Cancer Research Center (DE)
- ISA Pharmaceuticals (Netherlands) (NL)
- The Netherlands Cancer Institute (NL)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Zurich (CH)
- Leiden University Medical Center (NL)
- Corresponding author
- Schreiber, Robert D.
- ORCID
- Gubin, Matthew M.
- Zhang, Xiuli
- Schuster, Heiko
- Ward, Jeffrey P.
- Noguchi, Takuro
- Hundal, Jasreet
- Arthur, Cora D.
- Toebes, Mireille
- Vesely, Matthew D.
- Lam, Samuel S. K.
- Korman, Alan J.
- Allison, James P.
- Freeman, Gordon J.
- Sharpe, Arlene H.
- Pearce, Erika L.
- Schumacher, Ton N.
- Aebersold, Ruedi
- Rammensee, Hans-Georg
- Melief, Cornelis J. M.
- Mardis, Elaine R.
- Gillanders, William E.
- Artyomov, Maxim N.
- Schreiber, Robert D.
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 577-581
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4279952
- OpenAlex
- W2079018735
- Cited by
- 1,974
- References
- 48
- Citations by year
- 2026: 58 · 2025: 94 · 2024: 123 · 2023: 145 · 2022: 174 · 2021: 216 · 2020: 206 · 2019: 203 · 2018: 194 · 2017: 190 · 2016: 195 · 2015: 165 · 2014: 8
- FWCI
- 89.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (5u01ca141541-02)
- National Cancer Institute (P50CA101942, R01CA043059, U01-CA141541, R37CA043059, R01CA190700, P30CA016672, T32CA009547, P30CA091842)
- National Institute of Allergy and Infectious Diseases (P01AI054456, R01AI091965)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, immune checkpoint blockade, anti-PD-1, anti-CTLA-4, CD8+ T cell responses, therapeutic vaccines, personalized cancer vaccines, tumor antigens, long peptide vaccine, tumor immunosuppression, tumor regression
- MeSH terms
- Animals, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Immunotherapy, Male, Sarcoma, Vaccines, Synthetic, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.